ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE (ALCAM) AND OUTCOMES IN ACUTE CORONARY SYNDROMES: A PLATO BIOMARKER SUBSTUDY  by Wallentin, Lars et al.
A231
JACC March 17, 2015
Volume 65, Issue 10S
Acute Coronary Syndromes
activated leukocyte cell adhesion molecule (alcam) and outcomes in acute 
coRonaRy syndRomes: a plato biomaRkeR substudy
Poster Contributions
Poster Hall B1
Monday, March 16, 2015, 9:45 a.m.-10:30 a.m.
Session Title: Conquering the Platelet and More for Better Outcomes
Abstract Category: 2. Acute Coronary Syndromes: Clinical
Presentation Number: 1244-067
Authors: Lars Wallentin, Annika E. Michelsen, Pål Aukrust, Richard Becker, Maria Bertilsson, Andrzej Budaj, Jan Cornel, Anders 
Himmelmann, Steen Husted, Agneta Siegbahn, Robert Storey, Frederic Kontny, Thor Ueland, Department of Medical Sciences, Cardiology, 
and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
background:  Patients with acute coronary syndromes (ACS) have enhanced systemic leukocyte activation that may influence atheroma 
progression and plaque stability. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype through T-cell 
mediated mechanisms. We hypothesized that activated leukocyte cell adhesion molecule (ALCAM), a product of activated leukocytes, 
might predict outcomes in ACS.
methods:  ALCAM was determined in serum collected at randomization to ticagrelor or clopidogrel in 4185 patients with ACS in the PLATO 
(PLATelet inhibition and patient Outcomes) trial. Baseline characteristics were compared between groups stratified by quartiles of ALCAM 
by Chi-square test for categorical or Kruskal-Wallis test for continuous variables. The association between ALCAM and primary outcome, 
a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI) or stroke (events=362) was analyzed by Cox proportional 
hazards models.
Results:  The median (interquartile range) of baseline ALCAM was 92 (77-112) ng/mL. ALCAM levels were associated with multiple 
baseline characteristics, however, the strongest predictors for high ALCAM levels were female sex, non-STEMI, chronic renal disease, 
diabetes and heart failure. Baseline ALCAM was associated with the primary outcome in univariate analysis (HR 1.25 95% CI [1.10-1.42] 
p=0.0005), and after adjustment for baseline characteristics (p=0.048) but not after further adjustment for other biomarkers (i.e. CRP, 
cystatin C, TnT and NT-proBNP) (p=0.23). The association was strongest for CV death (events=89, univariate 1.66 [1.29-2.15] p<0.0001). 
However, significance was lost after adjustment for other biomarkers, (1.31 [0.98-1.75] p=0.071). There was no significant interaction 
between ALCAM and any effect of randomized treatment.
conclusion:  In patients with ACS, high serum levels of ALCAM were associated with adverse outcomes and in particular CV death. 
This association was no longer significant after extensive multivariable adjustment including other biomarkers. ALCAM did not identify 
subgroups of patients with specific responses to ticagrelor vs clopidogrel treatment.
